The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
May 2nd 2024
A recent meta-analysis that assessed prescribed exercise in managing multiple sclerosis (MS) detailed the benefits of resistance training for improving muscle weakness in this patient population.
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Making Treatment Decisions When There Is an Abundance of Options
September 13th 2014Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis, the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Read More
The Power of Treating Patients as Partners in MS Clinical Research
September 13th 2014As a medium, the Internet neither helps nor harms in multiple sclerosis care - what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of innovation at PatientsLikeMe.
Read More
Improving Patient-Clinician Communication and Treatment Adherence
September 12th 2014Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Read More
Engaging Patients in Their Own Treatment Decisions
September 12th 2014Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Read More
Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult
September 12th 2014The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Read More
PML is Treatable in MS, but Long-Term Function Can Remain Affected
September 11th 2014Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Read More
Using Advanced Imaging Techniques to Better Understand MS Progression
September 11th 2014Advanced imaging techniques are becoming necessary to further understanding of the progression of multiple sclerosis, according to presenters at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13.
Read More
Collaborative Decision Making Tops Efficacy for MS Patients
September 11th 2014When choosing treatment for a patient, whether he or she has a clinically isolated syndrome or clinically definite multiple sclerosis, providers need to establish a collaborative relationship, according to speakers at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Read More
The Burden of Soaring Prices of Specialty Drugs
April 16th 2014Even as the cost of prescription drugs has plummeted for many Americans, a small slice of the population is being asked to shoulder more and more of the cost of expensive treatments for diseases like cancer and hepatitis C, according to a report to be released on Tuesday by a major drug research firm.
Read More
Chronically Ill Face High Out-of-Pocket Costs
March 3rd 2014Those with chronic illnesses such as leukemia, hepatitis C, and multiple sclerosis may face a significant increase in their out-of-pocket expenses for specialty drugs. This is because payers are replacing fixed-dollar copayments with coinsurance rates that require patients to contribute a higher percentage of the cost for their specialty medications.
Read More
Patricia Coyle, MD, Discusses Treatment of Multiple Sclerosis
October 29th 2013Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute, professor and vice chair of clinical affairs, Department of Neurology, SUNY at Stony Brook, says that prognostically, the earlier you treat multiple sclerosis the better.
Read More
Strengthening the Assessment of Long-Term Treatment Outcomes in MS
October 4th 2013The gold standard for measuring treatment outcomes in multiple sclerosis (MS) is the randomized clinical trial (RCT). However, RCTs are often short-sighted and biased in their execution. Dr Maria Sormani, PhD, Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, addressed this problem in a lecture on immunomodulatory treatment of MS.
Read More
Fred Lublin, MD, Examines Research and Key Takeaways from ECTRIMS 2013
October 4th 2013In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.
Read More
A Look at the Widespread Economic Burden of Multiple Sclerosis
October 4th 2013Clinical trials and treatment in multiple sclerosis (MS) place an unwelcome economic burden upon countries with MS prevalence. With rising costs and a growing interest in MS clinical trials from emerging countries, new studies are needed to evaluate the significance of these factors.
Read More
Fatigue and Cognitive Impairment in Multiple Sclerosis
October 4th 2013Fatigue and cognitive impairment are 2 of the most common health problems associated with multiple sclerosis (MS). Recent MS studies evaluate the nature of these 2 conditions not just as side effects of MS, but as chronic conditions with varying degrees of severity based on objective assessment and self-perception.
Read More
Tecfidera and Ampyra Show Potential for Quality-of-Life Improvement in Patients With MS
October 4th 2013New disease-modifying drugs in multiple sclerosis (MS) show potential for improving quality-of-life (QoL) of patients with multiple sclerosis. The clinical benefits of dimethyl fumarate and PR-fampridine were discussed at a Biogen Idec-sponsored satellite symposium at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Read More